Results 21 to 30 of about 125,081 (292)

Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology [PDF]

, 2006
We investigated whether post-cardiac surgery (CS) new-onset atrial fibrillation (AF) is predicted by pre-CS atrial cellular electrophysiology, and whether the antiarrhythmic effect of beta-blocker therapy may involve pre-CS pharmacological remodeling ...
Kane, Kathleen A., Marshall, Gillian E., Norrie, John, Pau, David, Rankin, Andrew C., Redpath, Calum J., Russell, Julie A., Workman, Antony J.   +7 more
core   +1 more source

Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. [PDF]

, 2007
BACKGROUND: It is unclear whether beta-blocker therapy should be reduced or withdrawn in patients who develop acute decompensated heart failure (HF). We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a
A,, C,, Cas, Dei, Cleland,, Jg,, K,, Komajda,, L,, Lenarda, Di, M,, Metra, M, P,, Pa,, Poole-Wilson,, Remme,, Spark,, Swedberg,, Torp-Pedersen,, Wj,   +18 more
core   +1 more source

An Update on the Use of Molecularly Imprinted Polymers in Beta-Blocker Drug Analysis as a Selective Separation Method in Biological and Environmental Analysis

Molecules, 2022
Beta-blockers are antihypertensive drugs and can be abused by athletes in some sport competitions; it is therefore necessary to monitor beta-blocker levels in biological samples.
Aliya Nur Hasanah, Ike Susanti, Mutakin Mutakin   +2 more
doaj   +1 more source

Effect of visit-to-visit variation of heart rate and systolic blood pressure on outcomes in chronic systolic heart failure: results from the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) trial [PDF]

, 2016
Background: Elevated resting heart rate (HR) and low systolic blood pressure (SBP) are related to poor outcomes in heart failure (HF). The association between visit-to-visit variation in SBP and HR and risk in HF is unknown. Methods and Results:
Borer, Jeffrey, Böhm, Michael, Ewen, Sebastian, Ford, Ian, Komajda, Michel, Mahfoud, Felix, Robertson, Michele, Swedberg, Karl, Tavazzi, Luigi   +8 more
core   +1 more source

Effect of beta-blocker therapy on the risk of infections and death after acute stroke--a historical cohort study. [PDF]

PLoS ONE, 2015
BACKGROUND:Infections are a frequent cause for prolonged hospitalization and increased mortality after stroke. Recent studies revealed a stroke-induced depression of the peripheral immune system associated with an increased susceptibility for infections.
Ilko L Maier, André Karch, Rafael Mikolajczyk, Mathias Bähr, Jan Liman   +4 more
doaj   +1 more source

PENGARUH PENGGUNAAN BETA BLOCKER TOPIKAL JANGKA PANJANG TERHADAP SENSIBILITAS KORNEA PADA PASIEN GLAUKOMA

Jurnal Kedokteran Diponegoro, 2017
Latar Belakang : Penurunan sensibilitas kornea merupakan salah satu efek samping dari penggunaan beta blocker topikal yang dapat menimbulkan berbagai masalah seperti penurunan reflex mengedip, penurunan kemampuan penyembuhan luka pada kornea, dan terkait
Tusita Devi, Fifin Luthfia Rahmi
doaj   +1 more source

Association Between Lipophilic Beta-Blockers and Depression in Diabetic Patients on Chronic Dialysis

Clinical Medicine Insights: Endocrinology and Diabetes, 2022
Background: Depression is associated with lower quality of life and increased risk of mortality. The prevalence of depression in chronic dialysis patients, as well as in patients with diabetes, is more than 20%. It is debated whether use of beta-blockers
Robin Lengton, Robbert W Schouten, Els Nadort, Elisabeth FC van Rossum, Friedo W Dekker, Carl EH Siegert, Ellen K Hoogeveen   +6 more
doaj   +1 more source

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Current patterns of beta‐blocker prescription in cardiac amyloidosis: an Italian nationwide survey

ESC Heart Failure, 2021
Aims The use of beta‐blocker therapy in cardiac amyloidosis (CA) is debated. We aimed at describing patterns of beta‐blocker prescription through a nationwide survey.
Giacomo Tini, Francesco Cappelli, Elena Biagini, Beatrice Musumeci, Marco Merlo, Lia Crotti, Matteo Cameli, Gianluca Di Bella, Alberto Cipriani, Francesca Marzo, Federico Guerra, Cinzia Forleo, Christian Gagliardi, Mattia Zampieri, Samuela Carigi, Pier Filippo Vianello, Giulia Elena Mandoli, Giuseppe Ciliberti, Luca Lichelli, Davide Mariani, Aldostefano Porcari, Domitilla Russo, Roberto Licordari, Alberto Ponziani, Italo Porto, Federico Perfetto, Camillo Autore, Claudio Rapezzi, Giafranco Sinagra, Marco Canepa   +29 more
doaj   +1 more source

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome [PDF]

, 2008
Background: Progressive enlargement of the aortic root, leading to dissection, is the main cause of premature death in patients with Marfan's syndrome. Recent data from mouse models of Marfan's syndrome suggest that aortic-root enlargement is caused by ...
Brooke, Benjamin S., Dietz, Harry C., Habashi, Jennifer P., Judge, Daniel P., Loeys, Bart, Patel, Nishant   +5 more
core   +2 more sources